Condition 1: Patients who are candidates for hysteroscopy. Condition 2: Patients who are candidates for hysteroscopy. Noninflammatory disorder of uterus, unspecified Inflammatory disease of uterus, unspecified
Conditions
Interventions
Intervention 1: 100 mcg sublingual misoprostol 12 hours before hysteroscopy,. Intervention 2: 200 mcg sublingual misoprostol 12 hour before hysteroscopy. Intervention 3: 100 mcg rectal misoprostol 12
Diagnosis
100 mcg sublingual misoprostol 12 hours before hysteroscopy,
200 mcg sublingual misoprostol 12 hour before hysteroscopy
100 mcg rectal misoprostol 12 hour before hysteroscopy
200 mcg rectal misoprostol 12 hour before hysteroscopy
100 mcg vaginal misoprostol 12 hour before hysteroscopy
200 mcg vaginal misoprostol 12 hour before hysteroscopy
Sponsors
Tabriz University of medical science
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Inclusion criteria: All the patients who need diagnostic hysteroscopy and surgery such as: irregular uteral bleeding; inter uteral lesions in hysterosalpangography or sonography. Exclusion criteria: pregnancy; urinary tract infection; history of previous cervix surgery; cervix failure; patient dissatisfaction and prohibition prostaglandin intake
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cervix dilation for hysteroscopy. Timepoint: During hysteroscopy. Method of measurement: Hegar. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduce hysteroscopy's complications. Timepoint: After hysteroscopy. Method of measurement: By examination.;Reduce pain during hysteroscopy. Timepoint: During hysteroscopy. Method of measurement: Ask from patient. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed